The GLP-1 blind spot: Why the FDA’s new eye stroke warning matters

Summary
It forces the medical community to treat these therapies with clinical gravity instead of casual enthusiasm.
Description from The Hill.
Who is covering this
-
The GLP-1 blind spot: Why the FDA’s new eye stroke warning matters
It forces the medical community to treat these therapies with clinical gravity instead of casual enthusiasm.






Comments
Comments need JavaScript.